ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2014
Live bacterial vaccine vectors: an overview.
Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- SFV Replicon Vector Harbouring Porcine Epidemic Diarrhoea Virus Immunogens Delivered by AttenuatedViruses · 2026Article
- Review
- Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines.Vaccines · 2025Review
- Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches.Digestive diseases and sciences · 2025Review
- Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology.Microbial biotechnology · 2025Review
- Induction of protective immune responses at respiratory mucosal sites.Human vaccines & immunotherapeutics · 2024Review
- Genetic engineering ofEcoSal Plus · 2024Review
- Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria.Materials today. Bio · 2024Review
- Intracellular Survival and Pathogenicity Modulation ofInternational journal of molecular sciences · 2024Article
- Enteral Route Nanomedicine for Cancer Therapy.International journal of nanomedicine · 2024Review
- Bacterial Drug Delivery Systems for Cancer Therapy: "Why" and "How".Pharmaceutics · 2023Review
- Review
- Review
- Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment.Frontiers in immunology · 2023Review
- A SARS-CoV-2 oral vaccine development strategy based on the attenuated Salmonella type III secretion system.Journal of applied microbiology · 2022Article
- An Engineered Outer Membrane-DefectiveJournal of microbiology and biotechnology · 2022Article
- COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.Journal of microbiology (Seoul, Korea) · 2022Review
- Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins.Vaccine · 2022Article
- Use ofFrontiers in microbiology · 2022Article
- Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically attenuated microorganisms, pathogens, and some commensal bacteria can be engineered to deliver recombinant heterologous antigens to stimulate the host immune system, while still offering good levels of safety. A key feature of these live vectors is their capacity to stimulate mucosal as well as humoral and/or cellular systemic immunity. This enables the use of different forms of vaccination to prevent pathogen colonization of mucosal tissues, the front door for many infectious agents. Furthermore, delivery of DNA vaccines and immune system stimulatory molecules, such as cytokines, can be achieved using these special carriers, whose adjuvant properties and, sometimes, invasive capacities enhance the immune response. More recently, the unique features and versatility of these vectors have also been exploited to develop anti-cancer vaccines, where tumor-associated antigens, cytokines, and DNA or RNA molecules are delivered. Different strategies and genetic tools are constantly being developed, increasing the antigenic potential of agents delivered by these systems, opening fresh perspectives for the deployment of vehicles for new purposes. Here we summarize the main characteristics of the different types of live bacterial vectors and discuss new applications of these delivery systems in the field of vaccinology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.